Traferox FDA Approval Signals a New Era for Organ Transplantation

MISSISSAUGA, Ontario – July 22, 2026 – In a move that promises to reshape the landscape of organ transplantation, Traferox Technologies announced today that it has received Premarket Approval (PMA) from the U.S. Food and Drug Administration for its TorEx® Lung Perfusion System. This approval is more than a regulatory milestone; it represents a critical inflection point in the long-standing battle against organ shortages, equipping clinicians with a powerful tool to turn previously discarded donor lungs into life-saving opportunities.

The TorEx system is an ex vivo lung perfusion (EVLP) platform, a class of technology that keeps donor organs functioning in a near-physiologic state outside the body. This allows transplant teams to assess, and in some cases rehabilitate, lungs that would have been deemed too high-risk under traditional cold storage evaluation. Given that a staggering 80% of potential donor lungs in the U.S. are historically discarded due to uncertainty about their viability, the implications of this technology are profound.

"FDA approval of TorEx represents an important milestone for Traferox and, more importantly, for the thousands of patients waiting for a life-saving lung transplant in the United States," said Rick Mangat, Chief Executive Officer of Traferox Technologies. This technology, he noted, is the culmination of years of collaboration between clinicians, scientists, and engineers.

The Technology of a Second Chance

At its core, the TorEx system addresses a fundamental limitation in organ transplantation: the inability to fully assess an organ's function on ice. Traditional cold preservation slows metabolic decay but offers little insight into how a lung will perform once transplanted. EVLP changes the paradigm. By perfusing the lungs with a warm, nutrient-rich solution (TorEx Lung Perfusate) and ventilating them, the system allows surgeons to observe organ function in real-time.

"By evaluating donor lungs outside the body under physiologic conditions, clinicians can better understand organ function, allowing many donor lungs that might otherwise have been declined to be safely transplanted," explained Dr. Shaf Keshavjee, Chief Medical Officer of Traferox and a pioneer of the underlying EVLP technique.

This approach, known as the "Toronto Technique," has been clinically validated for over a decade. Research from Toronto General Hospital, where the method originated and where Traferox co-founders Keshavjee and Dr. Marcelo Cypel lead key programs, shows that the implementation of EVLP doubled the hospital's lung transplant volume while maintaining excellent patient outcomes. The TorEx system effectively packages this proven, complex procedure into an intuitive, standardized platform. Early results are compelling: in over 400 procedures using TorEx, approximately 67% of evaluated marginal donor lungs were ultimately accepted for transplantation.

Reshaping the Transplant Marketplace

For Traferox, a 2021 spin-out of University Health Network, the TorEx approval solidifies its rapid ascent into a market leader. This is the company's second major U.S. launch, following the successful rollout of its X°Port Lung Preservation System in 2025. The X°Port, a 10°C cold storage device, has already achieved remarkable market penetration, adopted by seven of the ten highest-volume U.S. lung transplant centers.

"The rapid adoption of our 10°C X°Port Lung Preservation System has demonstrated that transplant programs value technologies that are intuitive to use, supported by robust clinical evidence, and which offer a sustainable value proposition," stated Joe Kletzel, President of Traferox. The company is betting that TorEx will follow a similar trajectory.

This strategic sequencing—first providing a better preservation solution, then a revolutionary assessment platform—is no accident. It allows Traferox to build an ecosystem of trust and integration within transplant centers. A hospital already using X°Port for transport is a natural customer for TorEx for assessment, creating a powerful competitive advantage in a market that includes established players like TransMedics, XVIVO Perfusion, and a new centralized service model from United Therapeutics.

The economic case presents a more complex, yet equally compelling, narrative. A Canadian health economic analysis estimated that EVLP implementation saved the Ontario healthcare system over $20 million annually, primarily through shorter waitlist times and reduced post-operative costs. While the cost-benefit analysis in the fragmented U.S. healthcare system is still evolving—with some studies suggesting higher initial costs for EVLP, particularly at lower-volume centers—the overarching value proposition is clear. By increasing the supply of a scarce resource (viable lungs), the technology has the potential to decrease the immense downstream costs associated with managing patients on long-term oxygen, frequent hospitalizations, and lost productivity as they wait for a transplant.

A New Horizon for Patients and Providers

The ultimate impact of the TorEx system is measured in lives changed. For thousands of patients on the lung transplant waitlist, time is the enemy. Clinical deterioration while waiting is a primary driver of poor outcomes and mortality. By expanding the donor pool, EVLP technology directly shortens wait times, allowing patients to receive transplants before their health declines further.

"Evaluating donor lungs under normothermic physiologic conditions provides transplant teams with critical functional information that cannot be obtained through conventional donor assessment alone," noted Dr. Marcelo Cypel, Chief Scientific Officer of Traferox. This added information builds confidence and empowers surgeons to accept organs they would have previously been forced to decline.

The introduction of technologies like TorEx also signals a shift in the logistics and ethics of organ allocation. It necessitates new workflows in hospitals and organ procurement organizations and places a greater emphasis on the surgeon's final judgment, which remains paramount. As the line between "unsuitable" and "re-assessable" blurs, it reinforces the need for transparent communication with patients and families about the advanced techniques being used to make their life-saving transplant possible.

With this FDA approval, Traferox is not merely selling a machine; it is commercializing hope and efficiency. By combining advanced preservation with sophisticated assessment, the company is providing a comprehensive solution that addresses the entire organ journey, from donor to recipient. This integrated strategy is poised to not only expand access to lung transplantation but also to set a new standard for what is possible in the field.